Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

KOD

Kodiak Sciences Inc

Last Close
99.18
Oct 30 • 3:59 PM ET Dollar change-1.22 Percentage change(-1.22%)
Aftermarket Close
99.23
Aftermarket • 7:44 PM ET Dollar change+0.05 Percentage change(0.05%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Mid NASD
Peers: OCUL EYPT FDMT REGN BLTE RGNX OTLK OCGN ROIV HROW
 | Held by: XBI VTI IWM IBB VXF IWO VTWO SCHA FESM TMSL
Scroll to Statements
Index
RUT
Market Cap
6.23B
Enterprise Value
6.26B
Income
-241.99M
Sales
0.00M
Book/sh
0.97
Cash/sh
2.00
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
124
IPO
Oct 04, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
102.00
P/C
49.51
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
2.49
Current Ratio
2.49
Debt/Eq
2.50
LT Debt/Eq
2.34
Option/Short
Yes / Yes
EPS (ttm)
-4.19
EPS next Y
-3.85
EPS next Q
-1.06
EPS this Y
5.58%
EPS next Y
5.61%
EPS next 5Y
50.98%
EPS past 3/5Y
12.22% -8.23%
Sales past 3/5Y
- -
EPS Y/Y TTM
-10.60%
Sales Y/Y TTM
-
EPS Q/Q
-1.85%
Sales Q/Q
-
Earnings
Aug 13 AMC
EPS/Sales Surpr.
-9.78% -
Insider Own
8.55%
Insider Trans
53.89%
Inst Own
103.29%
Inst Trans
4.95%
ROA
-94.25%
ROE
-368.37%
ROIC
-118.60%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
7.79%
SMA50
55.64%
SMA200
135.62%
Trades
Shs Outstand
62.83M
Shs Float
57.48M
Short Float
14.79%
Short Ratio
5.01
Short Interest
8.50M
52W High
104.00 -4.63%
52W Low
15.83 526.40%
Volatility
6.41% 7.55%
ATR (14)
6.60
RSI (14)
66.45
Beta
2.02
Rel Volume
0.34
Avg Volume
1.70M
Volume
568,131
Perf Week
13.18%
Perf Month
0.73%
Perf Quarter
149.01%
Perf Half Y
125.61%
Perf YTD
254.72%
Perf Year
371.16%
Perf 3Y
6884.51%
Perf 5Y
-15.30%
Perf 10Y
-
Recom
1.33
Target Price
121.67
Prev Close
100.40
Price
99.18
Change %
-1.22%
Consensus
Strong Buy
Avg. Price Target
$121.67
Implied Upside
+22.7%
Analysts9incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 24, 2026Resumed
GS logoGGoldman
Neutral$36-63.7%
May 11, 2026Upgrade
CChardan Capital Markets
Neutral → Buy$61-38.5%
Nov 11, 2025Upgrade
HH.C. Wainwright
Neutral → Buy$24-75.8%
Oct 24, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$24-75.8%
Sep 25, 2025Upgrade
BCS logoBBarclays
Underweight → Equal Weight$17-82.9%
Sep 22, 2025Initiated
JEF logoJJefferies
Buy$15-84.9%
Aug 14, 2025Upgrade
JPM logoJJP Morgan
Underweight → Neutral$15-84.9%
Dec 09, 2024Upgrade
JEF logoJJefferies
Hold → Buy$20-79.8%
Sep 05, 2024Initiated
HH.C. Wainwright
Neutral$3-97.0%
Dec 11, 2023Resumed
GS logoGGoldman
Sell$2-98.0%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yang TaiyinDirectorOct 23 '26Option Exercise2.3520,00047,00020,000Oct 26 05:00 PM
BORGESON JOHN A.Chief Financial OfficerOct 21 '26Option Exercise2.4930,00074,700241,930Oct 23 05:00 PM
BORGESON JOHN A.Chief Financial OfficerOct 21 '26Sale90.0130,0002,700,322211,930Oct 23 05:00 PM
JOHN BORGESONOfficerOct 21 '26Proposed Sale92.9730,0002,789,100Oct 21 04:21 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy88.77681,86660,529,35420,159,386Sep 30 04:31 PM
BAKER BROS. ADVISORS LPDirectorSep 29 '26Buy85.0533,7262,868,25520,191,214Sep 30 04:31 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy83.58418,32334,963,07719,515,907Sep 30 04:30 PM
BAKER BROS. ADVISORS LPDirectorSep 28 '26Buy72.57807,84058,625,70819,121,134Sep 30 04:29 PM
PERLROTH VICTORChairman and CEOSep 25 '26Option Exercise4.201,280,5245,381,9433,676,062Sep 29 07:44 PM
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Option Exercise1.0430,00031,200241,930Jun 05 05:56 PM
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Sale34.1030,0001,023,009211,930Jun 05 05:56 PM
JOHN BORGESONOfficerJun 04 '26Proposed Sale33.8730,0001,016,100Jun 04 04:29 PM
BORGESON JOHN A.Chief Financial OfficerApr 15 '26Option Exercise1.0428,61429,759211,930Apr 16 05:00 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Option Exercise1.0430,00031,200213,316Apr 02 08:26 PM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Sale39.9230,0001,197,488183,316Apr 02 08:26 PM
JOHN BORGESONOfficerApr 02 '26Proposed Sale42.8130,0001,284,300Apr 02 04:23 PM
PERLROTH VICTORChairman and CEOMar 25 '26Option Exercise1.04300,000312,0002,395,538Mar 27 06:08 PM
BAKER BROS. ADVISORS LPDirectorDec 18 '25Buy23.002,608,69660,000,00818,358,772Dec 19 04:06 PM
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Co-FounderDr. Victor Perlroth M.D.
M.B.A.Mr. John A. Borgeson CPA
Chief Technology OfficerMr. Wayne To M.Phil.
M.P.H.Dr. Dolly S. Chang M.D.
Senior Vice President of DevelopmentDr. Hong Liang Ph.D.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)